Cargando…
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall...
Autores principales: | Nishida, Hiroko, Yamada, Taketo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875016/ https://www.ncbi.nlm.nih.gov/pubmed/31781214 http://dx.doi.org/10.1155/2019/6084012 |
Ejemplares similares
-
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018) -
Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018) -
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021) -
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019) -
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018)